CDX/Syngeneic Models

NexusPharma, in collaboration with its sister company, Invivotek, has a growing biobank of murine syngeneic and human cancer derived cell line models. These cell lines can be implanted as orthotopic, subcutaneous, metastatic, or disseminated models.

Cell line-derived xenograft (CDX) models that utilize patient-derived tumor cells can provide a more individualized platform for immune-oncology research. CDX models establish a tumor-bearing system in vivo by implanting immunocompromised mice with cell lines derived from primary tumor tissue. They are an attractive preclinical tool as the xenotransplantation of human cell lines is easy to control, well established and allows for rapid evaluation of therapeutic agents. The molecular profiles of CDXs demonstrate broad similarity when compared to the primary tumor. Most importantly, from a pharmacological perspective, the response of CDXs to standard chemotherapies often recapitulates the donor patient’s response to the same treatment. Therefore, CDXs can complement tumor biopsies and PDXs and can be a source of tumor material for research purposes. CDXs offer an opportunity to generate tailored treatment regimens for those patients that cannot undergo surgery or an alternative invasive procedure.

All of our well-characterized CDX models include select molecular and clinical tumor data. Models include, but are not limited to:

  • B-cell line EBV-EBNA1 positive
  • B-Cell non-Hodgkin Lymphoma
  • B-Cell plasmacytoma
  • Breast adenocarcinoma
  • Breast adenocarcinoma, metastatic
  • Breast invasive ductal carcinoma, stage IIA, grade 3
  • Breast normal mammary gland
  • Burkitt’s Lymphoma
  • Cervix adenocarcinoma
  • Cervix squamous cell carcinoma
  • Clear cell renal cell carcinoma, CCRCC
  • Colon adenocarcinoma
  • Colon adenocarcinoma (KRAS mutated)
  • Colon adenocarcinoma (KRAS normal)
  • Colorectal carcinoma
  • Epidermoid carcinoma
  • Head and neck squamous cell carcinoma
  • HeLa derivative
  • Lung cancer, NSCLC
  • Lung non-small cell carcinoma, NSCLC
  • Bronchioalveolar carcinoma
  • Lung non-small cell carcinoma, NSCLC, large cell Adenocarcinoma
  • Lung small cell carcinoma, SCLC
  • Neuroblastoma
  • Normal foreskin fibroblasts
  • Ovarian carcinoma
  • Ovarian teratocarcinoma
  • Pancreatic ductal adenocarcinoma, PDAC
  • Prostate carcinoma metastatic
  • T-cell leukemia acute
  • Acute lymphoblastic leukemia, T-ALL
  • Urinary bladder carcinoma, grade II
  • Urinary bladder transitional cell carcinoma
  • Uterine carcinoma